{
    "clinical_study": {
        "@rank": "132976", 
        "acronym": "RetroMASTER", 
        "arm_group": [
            {
                "arm_group_label": "Responders", 
                "description": "Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months."
            }, 
            {
                "arm_group_label": "Progressors", 
                "description": "Patients with Type 2 diabetes that progressed to requiring insulin treatment \u226410 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis."
            }
        ], 
        "biospec_descr": {
            "textblock": "At Visit 1 a fasting blood sample (approximately 35 mls) will be taken for DNA extraction,\n      and to measure for markers of the progression of diabetes or response to diabetes medication\n      and for secondary markers that may predict response. A urine sample is also collected to\n      measure for biomarkers."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study will examine extreme responders to second- and third-line Type 2 Diabetes (T2D)\n      therapy using a retrospective approach and patients with slow or fast diabetes progression."
        }, 
        "brief_title": "RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "PILOT Phase (March 2013 - Dec 2014) Patients will be recruited initially from 2 centres,\n      plus Exeter as a pre-PILOT centre.  Patients with particularly good or poor response to\n      second- and third-line Type 2 diabetes treatments and patients progressing to insulin either\n      particularly quickly or particularly slowly will be recruited from primary, secondary, or\n      community settings.  Fasting blood and urine samples will be collected, along with standard\n      biomeasures and information will be collected about medical history and prescribing history.\n\n      All study documentation and sample materials will be sent out to sites from the coordinating\n      centre.  Sites will be expected to process and freeze samples and send them to the Central\n      Laboratory managed by the Chief Inspector's site where they will be analysed for genetic\n      factors, glycaemic markers and other markers related to drug response.\n\n      POST-PILOT Phase (Jan 2015- Oct 2017): Subject to feasibility, interim analysis and\n      continuation of funding from Medical Research Council (MRC), this project will continue for\n      another three years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Generic Inclusion Criteria:\n\n          -  Demographics: Age 18-90 inclusive\n\n          -  Ethnicity: Reflective of local demographic\n\n          -  Medical History: Clinical diagnosis of Type 2 diabetes\n\n          -  Mental Capacity: Capacity to Consent\n\n        Responders Cohort Inclusion Criteria:\n\n          -  On Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone for >\n             4 months.\n\n          -  Pre-treatment HbA1c\u2265 58mmol/mol (7.5%).\n\n        Progressors Cohort Inclusion Criteria:\n\n          -  Type 2 diabetes (not on insulin treatment within 6 months of diagnosis)\n\n          -  Either: requirement for insulin treatment \u226410 years from diagnosis (defined as\n             insulin treatment or HbA1c \u2265 69mmol/mol (8/5%) treated with two or more non-insulin\n             diabetes therapies) or: no requirement for insulin treatment >10 years from diagnosis\n             (defined as not on insulin treatment AND HbA1c <69mmol/mol (8.5%).\n\n        Exclusion Criteria:\n\n          -  Age less than 18 years old and greater than 90 years old\n\n          -  Incapacity to consent\n\n          -  Type 1 diabetes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants will be identified in primary care and secondary care. The method for patient\n        identification may differ between sites and could involve:\n\n        GP Searches; Secondary Care Clinician Referral; Research Database Searches."
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109978", 
            "org_study_id": "CRF117", 
            "secondary_id": "12/SW/0348"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Type 2 diabetes", 
            "Diabetes therapy response", 
            "Diabetes progression"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "c.angwin@exeter.ac.uk", 
                    "last_name": "Catherine Angwin, BA, MSc", 
                    "phone": "++44 1392 408185"
                }, 
                "contact_backup": {
                    "email": "m.hudson@exeter.ac.uk", 
                    "last_name": "Michelle Hudson, BSc", 
                    "phone": "++44 1392 408183"
                }, 
                "facility": {
                    "address": {
                        "city": "Exeter", 
                        "country": "United Kingdom", 
                        "state": "Devon", 
                        "zip": "EX2 5DW"
                    }, 
                    "name": "University of Exeter"
                }, 
                "investigator": {
                    "last_name": "Andrew T Hattersley, FAMS, FRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Nicky.Mcrobert@ouh.nhs.uk", 
                    "last_name": "Nicky McRobert"
                }, 
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom", 
                        "state": "Oxfordshire", 
                        "zip": "OX1 2JD"
                    }, 
                    "name": "University of Oxford"
                }, 
                "investigator": {
                    "last_name": "Stephen Gough", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nataliesmith1@nhs.net", 
                    "last_name": "Natalie Smith"
                }, 
                "contact_backup": {
                    "email": "E.J.Z.Gellatly@dundee.ac.uk", 
                    "last_name": "Emma Gellatly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "United Kingdom", 
                        "zip": "DD1 9SY"
                    }, 
                    "name": "University of Dundee"
                }, 
                "investigator": {
                    "last_name": "Ewan Pearson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "2", 
        "official_title": "Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes:", 
        "overall_contact": {
            "email": "c.angwin@exeter.ac.uk", 
            "last_name": "Catherine Angwin, BA; MSc", 
            "phone": "++44 1392 408185"
        }, 
        "overall_contact_backup": {
            "email": "m.hudson@exeter.ac.uk", 
            "last_name": "Michelle Hudson, BSc, PGCE", 
            "phone": "++44 1392 408183"
        }, 
        "overall_official": {
            "affiliation": "University of Exeter", 
            "last_name": "Andrew T Hattersley, FRCP, DM, BM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be to compare the clinical characteristics of the patients who show an excellent response or poor response to specific second- and third- line classes of treatment for Type 2 diabetes; and of those patients that show rapid progression of Type 2 diabetes or slow progression of Type 2 diabetes to markedly high blood glucose despite the treatment that they require.", 
            "measure": "Response to diabetes therapy and rate of diabetes progression", 
            "safety_issue": "No", 
            "time_frame": "Within 9 months from date of recruitment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To collect a set of DNA, serum and urine samples to allow analysis of potential genetic and non-genetic biomarkers for drug response and diabetes progression.", 
            "measure": "Collection of samples for analysis of potential biomarkers", 
            "safety_issue": "No", 
            "time_frame": "within 9 months of recruitment date"
        }, 
        "source": "NIHR Exeter Clinical Research Facility", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Exeter", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Royal Devon and Exeter NHS Foundation Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Oxford", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oxford University Hospitals NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Dundee", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "NHS Tayside", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "NIHR Exeter Clinical Research Facility", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}